Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis.
75 systemic sclerosis patients were independently tested for pulmonary fibrosis, autoantibodies, and MHC class II genes. 24 of 42 (57%) patients with pulmonary fibrosis had either HLA DR3/DRw52a or anti-Scl-70 vs 2 of 33 (6%) patients without pulmonary fibrosis. The presence of DR3/DRw52a or anti-Scl-70 gives a relative risk of 16.7 for the development of pulmonary fibrosis in a patient with scleroderma--a risk substantial enough to require careful monitoring of these patients and treatment at an early stage of disease.
Briggs
D C
DC
Department of Immunogenetics, Guy's Hospital, London, UK.
Vaughan
R W
RW
Welsh
K I
KI
Myers
A
A
duBois
R M
RM
Black
C M
CM
D001323:Autoantibodies / Q000032:analysis; D004247:DNA / Q000032:analysis; D004264:DNA Topoisomerases, Type I; D015803:HLA-DR3 Antigen / Q000235:genetics; D015805:HLA-DR5 Antigen / Q000235:genetics; D006239:Haplotypes / Q000235:genetics; D006801:Humans; D009687:Nuclear Proteins / Q000276:immunology; D011336:Probability; D011658:Pulmonary Fibrosis / Q000209:etiology* / Q000276:immunology; D012595:Scleroderma, Systemic / Q000150:complications* / Q000276:immunology
D001323:Autoantibodies; D015803:HLA-DR3 Antigen; D015805:HLA-DR5 Antigen; D009687:Nuclear Proteins; C048100:Scl 70 antigen, human; D004247:DNA; D004264:DNA Topoisomerases, Type I